| P50 | author | Roman M. Chicz | Q116383830 |
| | Mary Lynne Hedley | Q125023760 |
| P2093 | author name string | Mark Matijevic | |
| | Thomas M Luby | |
| | Christa Lajoie | |
| | Robert G Urban | |
| P2860 | cites work | HPV and Cervical Cancer: Updates on an Established Relationship | Q22305479 |
| | The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 | Q24317677 |
| | Structure of the complex between human T-cell receptor, viral peptide and HLA-A2 | Q27733853 |
| | The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product | Q29618372 |
| | DNA vaccines against human immunodeficiency virus type 1. | Q30342130 |
| | Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus | Q30368335 |
| | Management of anogenital warts (condylomata acuminata). | Q31029140 |
| | Poly-DL-lactide-co-glycolide microspheres as a controlled release antigen delivery system | Q33646641 |
| | Human papillomavirus infection and cervical carcinoma | Q33948231 |
| | Natural HPV immunity and vaccination strategies | Q34089071 |
| | Assays for monitoring cellular immune responses to active immunotherapy of cancer. | Q34249864 |
| | The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy. | Q34956064 |
| | Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein | Q34975376 |
| | Formulations containing poly(lactide-co-glycolide) and plasmid DNA expression vectors | Q35207503 |
| | ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial | Q35644707 |
| | Microparticles for the delivery of DNA vaccines | Q35826399 |
| | Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis | Q36230273 |
| | Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity | Q36312800 |
| | Role of the human papillomaviruses in human cancer | Q36418956 |
| | DNA vaccines: precision tools for activating effective immunity against cancer. | Q37064852 |
| | Immunobiology of HPV and HPV vaccines | Q37161653 |
| | Strategies for effective naked-DNA vaccination against infectious diseases. | Q37232680 |
| | Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer | Q37343083 |
| | Human papillomavirus vaccine and cervical cancer prevention | Q37345134 |
| | Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol | Q39681270 |
| | Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types | Q39684397 |
| | Use of interferon-gamma ELISPOT in monitoring immune responses in humans | Q39719347 |
| | Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. | Q40582374 |
| | A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. | Q40746658 |
| | Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood | Q41055872 |
| | Papillomavirus vaccines. | Q44196727 |
| | CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia | Q44310727 |
| | Looking for human papillomavirus type 16 by PCR. | Q44315821 |
| | Microparticle delivery of plasmid DNA to mammalian cells. | Q51725572 |
| | In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. | Q51727083 |
| | A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays | Q59650911 |
| | Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III | Q64382267 |
| | Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines | Q74343602 |
| | Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay | Q77552569 |
| | Cold-knife conization versus the loop electrosurgical excision procedure for treatment of cervical dysplasia | Q81010112 |
| | Regulatory T cells in a spectrum of HPV-induced cervical lesions: cervicitis, cervical intraepithelial neoplasia and squamous cell carcinoma | Q81560456 |
| | Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice | Q81624591 |
| P433 | issue | 1 | |
| P921 | main subject | immunization | Q1415366 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 62-69 | |
| P577 | publication date | 2011-04-23 | |
| P1433 | published in | Cellular Immunology | Q2597167 |
| P1476 | title | Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11. | |
| P478 | volume | 270 | |